Market Overview

UPDATE: JP Morgan Initiates IMAX Corporation with Overweight, $30 PT on Growth Outlook

Related IMAX
IMAX's Accelerated Screen Growth Should Drive Solid Long-Term Earnings Growth
The Street Isn't Seeing The Big Picture For IMAX

JP Morgan initiates its coverage on IMAX Corporation (NYSE: IMAX) with a rating of Overweight and a price target of $30.

JP Morgan notes, "We are initiating coverage of IMAX with an Overweight rating and $30 Dec 2012 price target. We find shares attractive for a high visibility, long-term growth story that is one of the few plays on emerging market box office growth. IMAX also benefits from a unique business model within the industry that delivers high profitability and recurring FCF generation with every screen added to its network. The company has established itself as a valuable brand to both consumers and filmmakers, which we expect will help maintain its advantaged position in the global theatrical industry."

IMAX closed at $24.03 on Friday.

Latest Ratings for IMAX

Sep 2016MacquarieMaintainsOutperform
Jul 2016Roth CapitalAssumesBuy
Mar 2016BenchmarkMaintainsBuy

View More Analyst Ratings for IMAX
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Initiation Intraday Update Analyst Ratings


Related Articles (IMAX)

View Comments and Join the Discussion!